Elsevier

Journal of Thoracic Oncology

Volume 6, Issue 8, August 2011, Pages 1435-1437
Journal of Thoracic Oncology

Brief Report
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

https://doi.org/10.1097/JTO.0b013e318223c099Get rights and content
Under an Elsevier user license
open archive

Introduction

KRAS mutations are present in 30% of lung adenocarcinomas. Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations.

Methods

Two cohorts of patients with stage IIIB/IV lung adenocarcinoma were eligible: patients with tumors with KRAS mutations who were previously treated with chemotherapy and patients receiving initial therapy who had ≥15 pack-year smoking history. Salirasib was given orally from days 1 to 28 of a 35-day cycle. The primary end point was the rate of nonprogression at 10 weeks.

Results

Thirty-three patients were enrolled. Thirty patients had KRAS mutations (23 patients who were previously treated and 7/10 patients who had no prior therapy). Of the previously treated patients, 7 of 23 (30%) had stable disease at 10 weeks, and 4 of 10 (40%) previously untreated patients had stable disease at 10 weeks. No patient had a radiographic partial response (0% observed rate, 95% confidence interval 0–12%). The median overall survival was not reached (>9 months) for previously untreated patients and it was 15 months for patients who received prior chemotherapy. Diarrhea, nausea, and fatigue were the most common toxicities.

Conclusions

Salirasib at the current dose and schedule has insufficient activity in the treatment of KRAS mutant lung adenocarcinoma to warrant further evaluation. The successful enrollment of 30 patients with tumors with KRAS mutant lung adenocarcinoma over 15 months at a single site demonstrates that drug trials directed at a KRAS-specific genotype in lung cancer are feasible.

Key Words

Lung adenocarcinoma
Salirasib
KRAS

Cited by (0)

Disclosure: Dr. Riely has been a compensated consultant for AstraZeneca, Boehringer-Ingelheim, Tragara, Ariad, and Chugai. This study was sponsored by Concordia Pharmaceuticals.

William Pao is currently at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

Melissa L. Johnson is currently at Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.